Non-steroidal anti-inflammatory drugs and risk of pulmonary embolism

Pharmacoepidemiology and Drug Safety

Volumn 20, Issue 6, 2011, Pages 635-642

  Biere Rafi, Sara ^c   Di Nisio, Marcello ^a   Gerdes, Victor ^c   Porreca, Ettore ^a   Souverein, Patrick ^b   de Boer, Anthonius ^b   Büller, Harry ^c   Kamphuisen, Pieter ^c  

^a UNIVERSITY OF CHIETI   (Italy)

^b UTRECHT UNIVERSITY   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Arterial thrombosis; Non steroidal anti inflammatory drugs; Venous thromboembolism

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETORICOXIB; IBUPROFEN; INDOMETACIN; KETOPROFEN; MELOXICAM; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PIROXICAM; TRAMADOL;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CONFOUNDING VARIABLE; CONTROLLED STUDY; DRUG INDICATION; FEMALE; HEMOSTASIS; HOSPITAL ADMISSION; HUMAN; LONG TERM CARE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; PAIN; POPULATION RESEARCH; PRIORITY JOURNAL; REGISTER; RISK ASSESSMENT; RISK FACTOR; STATISTICAL ANALYSIS; THROMBOGENICITY; TREATMENT DURATION;

ACETAMINOPHEN; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANALGESICS, NON-NARCOTIC; ANALGESICS, OPIOID; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CASE-CONTROL STUDIES; DATABASES, FACTUAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MEDICAL RECORD LINKAGE; MIDDLE AGED; NETHERLANDS; PULMONARY EMBOLISM; REGISTRIES; RISK FACTORS; TIME FACTORS; TRAMADOL; YOUNG ADULT;

EID: 79959564996     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.2130     Document Type: Article

References (18)

1. Bombardier C, Lain L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343: 1520-1528.
2. Bresalier R, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trail. N Engl J Med 2005; 352: 1092-1102.
3. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006; 332: 1302-1308.
4. Solomon SD, McMurray JJV, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005; 352: 1071-1080.
5. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006; 296: 1633-1644.
6. Combe B, Swergold G, McLay J, et al. Cardiovascular safety and gastrointestinal tolerability of etoricoxib vs diclofenac in a randomized controlled clinical trial (The MEDAL study). Rheumatology 2009; 48: 425-432.
7. Van Staa TP, Rietbrock S, Setakis E, Leufkens HGM. Does the varied use of NSAIDs explain the differences in the risk of myocardial infarction? J Intern Med 2008; 264: 481-492.
8. Fosbol EL, Gislason GH, Jacobsen S, et al. Risk of myocardial infarction and death associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDs) among healthy individuals: a nationwide cohort study. Clin Pharmacol Ther 2009; 85: 190-197.
9. Catella-Lawson F, Crofford LJ. Cyclooxygenase inhibition and thrombogenicity. Am J Med 2001; 110(3A): 28S-32S.
10. Graff J, Skarke C, Klinkhardt U, et al. Effects of selective COX-2 inhibition on prostanoids and platelet physiology in young healthy volunteers. J Thromb Haemost 2007; 5: 2376-2385.
11. Rabausch K, Bretschneider E, Sarbia M, et al. Regulation of thrombomodulin expression in human vascular smooth muscle cells by COX-2-derived prostaglandins. Circ Res 2005; 96(1): e1-e6.
12. Bishop-Bailey, Pepper JR, Larkin SW, Mitchell JA. Differential induction of cyclooxygenase-2 in human arterial and venous smooth muscle: role of endogenous prostanoids. Arterioscler Thromb Vasc Biol 1998; 18: 1655-1661.
13. Huerta C, Johansson S, Wallander MA, García Rodríguez LA. Risk factors and short-term mortality of venous thromboembolism diagnosed in the primary care setting in the United Kingdom. Arch Intern Med 2007; 167: 935-943.
14. Fosbøl EL, Gislason GH, Jacobsen S, et al. The pattern of use of non-steroidal anti-inflammatory drugs (NSAIDs) from 1997 to 2005: a nationwide study on 4.6 million people. Pharmacoepidemiol Drug Saf 2009; 17: 822-833.
15. Arellano FM, Yood MU, Wentworth CE, et al. Use of cyclo-oxygenase 2 inhibitors (COX-2) and prescription non-steroidal anti-inflammatory drugs (NSAIDs) in UK and USA populations. Pharmacoepidemiol Drug Saf 2008; 17: 1037.
16. Ageno W, Agnelli G, Imberti D, et al. Factors associated with the timing of diagnosis of venous thromboembolism: results from the MASTER registry. Thromb Res 2008; 121: 751-756.
17. Casez P, Labarère J, Sevestre MA. ICD-10 hospital discharge diagnosis codes were sensitive for identifying pulmonary embolism but not deep vein thrombosis. J Clin Epidemiol 2010; 63: 790-797.
18. Hinz B, Cheremina O, Brune K. Acetaminophen (paracetamol) is a selective cyclooxygenase-2 inhibitor in man. FASEB J 2008; 22: 383-390.